The University of Manchester, Manchester, United Kingdom

Group Description

Brief description of legal entity
The University of Manchester, formed in 2004 from the merger of two premier Universities, is the largest in the UK (annual turnover of almost 1bn Euros), and recognised for strength in research. In the last national exercise, it gained the top scores for research in biology and pre-clinical medicine. The Faculty of Life Sciences (FLS) is one of the largest and most successful unified research and teaching organisations of its kind in Europe, comprising over 250 independent research groups. The Faculty structure provides a highly interactive research environment with excellent local collaborations. Working across the FLS and the Faculty of Medicine and Human Sciences (School of Cancer and Enabling Sciences), Drs Emmanuel Pinteaux and Hervé Boutin have access to a broad range of outstanding analytical research facilities (e.g. microscopy, protein analysis, mass spectrometry, animal facilities including transgenic suite, preclinical MRI and PET-CT) and recent investment in new buildings to accommodate staff is >£150M. We have outstanding new laboratories and are well equipped to conduct all studies described. During the overall period of the European Network of Excellence DiMI, Dr Boutin was an active member and contributor of the network (WP9, neuroinflammation). As senior member of Prof. Nancy Rothwell lab, Dr Boutin has significantly contributed to the FP7-HEALTH grant application “Affording Recovery In Stroke” (ARISE). Leading the brain PET imaging activity at the Wolfson Molecular Imaging Centre, Dr. Boutin was co-applicant to the University Research Grant securing £600,000 to purchase a preclinical PET-CT (installed in June 2010).

Main tasks
Dr Pinteaux research focuses on identifying the cellular mechanisms regulating neuroinflammation and more specifically the action of interleukin-1 in glial cells and the contribution of the extracellular matrix in neuroinflammation. Dr Boutin’s research mainly focuses on i) identifying in vivo the processes (co-morbidities, risk factors) regulating neuroinflammation and how neuroinflammation may contribute to brain damage and neuronal loss in both acute (stroke) and chronic conditions (AD) and on ii) developing new PET radiotracers to answer these questions.

Participation in INMiND: WP1 / WP2 / WP3 / WP5 / WP6 / WP7.

Previous experience relevant to INMiND tasks

Development and validations of several TSPO tracers ([11C]CLINME, [11C]DPA-713, [18F]DPA-714, [11C]SSR180575 (patented)) to image microglial activation in models of acute and chronic brain damage; development of a new method of protein labelling with [18F] (patented); extensive experience in neuroinflammation (glial cell biology, interactions neuron-glia) and extracellular matrix biology; routine use of PET imaging and MRI in small animals (rats and transgenic mice).

University of Manchester
INMiND Office
European Institute for Molecular Imaging (EIMI) Waldeyerstr. 15
· 48149 Münster
Tel: +49 251 83 49300 · Fax: +49 251 83 49313